Portal de Periódicos da CAPES

Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

2016; Elsevier BV; Volume: 90; Issue: 6 Linguagem: Inglês

10.1016/j.kint.2016.09.010

1523-1755

Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, Brenda R. Hemmelgarn, Adeera Levin, Merlin C. Thomas, Christoph Wanner, Bertram L. Kasiske, David C. Wheeler, Per‐Henrik Groop, George L. Bakris, Mark E. Cooper, Dong‐Wan Chae, Michael H. Davidson, Ian H. de Boer, Dick de Zeeuw, Alessia Fornoni, Luigi Gnudi, Charles A. Herzog, Adriana M. Hung, Tazeen H. Jafar, Meg Jardine, Vivekanand Jha, Linong Ji, Steven E. Kahn, Robyn G. Langham, Edgar V. Lerma, Ronald C.W., Hirofumi Makino, Michel Marre, Michael Mauer, Kaj Metsärinne, Robert G. Nelson, Roberto Pecoits–Filho, Carol A. Pollock, Mohan Rajapurkar, Peter Rossing, Ivan Rychlík, Kumar Sharma, Robert C. Stanton, Vladimı́r Tesař, Ilkka Tikkanen, Charles Tomson, Robert D. Toto, Yusuke Tsukamoto, Katherine R. Tuttle, Takashi Wada, Winfred W. Williams, Hong Zhang, Sophia Zoungas,

Chronic Kidney Disease and Diabetes

The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.